Investors / Aim Rule 26

Aim Rule 26

Please click on the headings below to expand for more information.

Description of the Business

ECO Animal Health is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets.

Our products for these growth markets promote well-being in animals.

Proprietary patented drugs

Aivlosin® – macrolide antibiotic for treatment of respiratory & enteric diseases in pigs and poultry.

Information on Aivlosin

Generic drugs

Ecomectin® Ecoheart, Ecotraz & Ecomintic (endectocides & other antiparasitics) for treatment & prevention of parasites in cattle, sheep, pigs, horses and dogs.

Chlortetracycline & Oxytetracycline for treatment of bacterial infections in pigs, poultry & cattle.

For further information, visit our websites;
www.ecoanimalhealth.com
www.aivlosin.com

Country of incorporation and main country of operation

Registered in England and Wales number 01818170.

VAT registration number 523 9367 33.

Main country of operation is England.

Current Constitutional Documents
Details of any other exchanges or trading platforms on which the Company’s shares are admitted or traded

ECO Animal Health Group has only applied and agreed to have its securities traded on the AIM market of the London Stock Exchange.

Number of AIM Securities in Issue

The total number of ordinary shares in issue is 67,744,889. There are currently no shares held in treasury.

Last Updated 30 November 2023.

Share information

ECO Animal Health Group plc is currently trading on AIM.

Shares in issue No. of ordinary shares Percentage
Total issued share capital 67,744,889
Shares not in public hands 26.24

 

Significant Shareholders as at 30 November 2023

Shareholder Shares % IC
Schroder Investment Mgt 9,825,716 14.50
Soros Fund Mgt 7,715,642
11.39
Mr Peter A Lawrence 6,501,146 9.60
Lombard Odier Asset Mgt 4,522,974 6.68
AXA Investment Mgrs 4,347,893 6.42
Chelverton Asset Management 3,850,000 5.68
FIL Investment International 3,105,757 4.58
Details of any restrictions on the transfer of AIM Securities

There are no restrictions on the transfer of the company’s securities.

Recent Financial reports

Please refer to our Financial Reports page.

Notifications made by ECO Animal Health Group plc

Please refer to our Regulatory News page.

Details of admission documents
Corporate Governance
Names, Biographies and Responsibilities of the Directors

Dr Andrew Jones, PhD, BSc (Hons), Non-Executive Chairman
Andrew has over 34 years’ commercial experience in the life science sector and has held a range of senior positions, including CEO Europe for Arysta Lifescience, CEO Phoqus Pharmaceuticals plc, Principal at Cap Gemini Ernst and Young. He started his career in ICI Agrochemicals (now Syngenta AG).  He is also Non-Executive Chairman of Fargroup Limited a specialist horticultural distribution business supplying the UK market and Non-Executive Chairman of RootWave (Ubiqutek Ltd) a UK company developing technology and products that use electricity to kill weeds to provide a sustainable alternative to chemical herbicides.

He currently runs his own consulting Company, Trioza Limited, which provides strategic advice to the animal health, crop protection and seeds sectors.

Andrew has a BSc degree and PhD in agricultural biology.

Andrew brings substantial strategic marketing and business development experience and skills to the business.

David Hallas, Chief Executive Officer
David Hallas has over 30 years of experience in the animal health industry and is a qualified veterinarian. He is currently managing director of Sure Petcare, a wholly owned subsidiary of Merck Inc. providing digital based solutions to the companion animal sector with sales of over US$170m. Prior to this role, he was Associate Vice President of MSD Animal Health with full P&L responsibility for mid Europe which comprised a group of 7 European countries with a combined revenue of over US$450m; he has also held senior global, regional and business unit management roles in other animal health businesses within Merck, Schering Plough and Pfizer (now Zoetis) and lived and worked overseas including in the USA. David has substantial experience managing profitable growth through the introduction of new products, including vaccines, and successful merger and acquisition integrations.

Christopher Wilks FCA, BSc (Hons), CFO
Christopher Wilks has considerable experience in the fields of both finance and science. He is currently a non-executive director (and Chair of the Audit Committee) of Kromek Group plc, an AIM listed worldwide supplier of radiation detection technology and was previously Chief Financial Officer of Signum Technology Limited, a leading group of specialised engineering businesses operating in the safety and critical service flow control sector, which he co-founded. Prior to Signum Technology, Mr Wilks was Chief Financial Officer at Sondex plc, a specialist manufacturer of technical instruments for the oil and gas industry. Mr Wilks became the Chief Financial Officer of Sondex in 1997 and in June 2003 he successfully managed the listing of Sondex plc on the Main Market of the London Stock Exchange. Sondex was acquired by GE in 2007.

Chris began his career after graduating from the University of Durham with a BSc in Applied Physics and Electronics. Initially he joined Marconi Space Systems, applying his degree skills to the design of power systems for spacecraft. He then trained as a Chartered Accountant at Arthur Young (now EY), and after qualifying as a Chartered Accountant in audit, he became a manager in its Corporate Finance team. Mr Wilks is a Fellow of the Institute of Chartered Accountants in England and Wales.

Dr Frank Armstrong, Non-Executive Director
Frank is a medical doctor, a Fellow of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine. He is currently Non-Executive Chair of Faron Pharmaceutical Oy (AIM), Non-Executive Chair of BioCaptiva Limited, Non-Executive Chair of Enhanc3D Ltd, Non-Executive Chair of Bloomsbury Genetic Therapies Limited (BGT), a Non-Executive Director of Newcells Biotech Ltd and a Member of the Court of the University of Edinburgh. He has previously held Non-Executive roles in listed companies with Summit Therapeutics (AIM and NASDAQ), Redx Pharma (AIM), Mereo Biopharma (AIM and NASDAQ) and Juniper Therapeutics (NASDAQ). He started his career at ICI Pharma/Zeneca Pharma before moving to Bayer AG where he became head of worldwide product development.

Tracey James, Non-Executive Director
Tracey is a Chartered Accountant who has spent 26 years with Grant Thornton UK LLP, with the last 14 years as an Audit Partner. Tracey was a member of Grant Thornton’s Oversight Board and also served on the Audit & Risk and Pensions Committees. She was also previously Finance Director of Karl Storz Endoscopy Canada (1999-2000). Tracey is currently a Non-Executive Director and Chair of the Audit Committee at specialist Engineering and Technology recruitment solutions business, Gattaca plc.

Board Committees and members

Audit Committee

Tracey James (Chair)
Andrew Jones
Frank Armstrong

Remuneration Committee

Frank Armstrong (Chair)
Andrew Jones
Tracey James

Nomination Committee

Andrew Jones (Chair)
Frank Armstrong
Tracey James

City Code on Takeover and Mergers

The Company is subject to the UK City Code on Takeovers and Mergers.

Details of the nominated advisers and key advisers

Nominated Advisor and Broker

Singer Capital Markets
1 Bartholomew Lane
London
EC2N 2AX

Tel: +44 (0) 20 7496 3069

Joint Broker

Investec
30 Gresham Street
London
EC2V 7QN

Tel: +44 (0)  20 7597 5970

Registered Auditors

Haysmacintyre LLP
10 Queen Street Place,
London
EC4R 1AG

Registrars

Share Registrars Limited
3 The Millennium Centre,
Crosby Way,
Farnham
GU9 7XX

Tel: +44 (0)1252 821390
Web: www.shareregistrars.uk.com

The above information has been disclosed pursuant to Rule 26 of the AIM Rules for Companies.

Broker Coverage

Learn more

Advisors/Registrars

Learn more

Share Price

Learn more